Login to Your Account

FDA Panel Backs HGSI's Benlysta for Lupus

By Donna Young

Wednesday, November 17, 2010
ADELPHI, Md. – An FDA panel in a 13-to-2 vote Tuesday recommended approval for Human Genome Sciences Inc.'s Benlysta (belimumab) as a treatment for adults with systemic lupus erythematosus (SLE), a chronic debilitating autoimmune disease that primarily affects women of childbearing age, although men, children and teenagers have been known to develop the condition. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription